Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.O)

MNTA.O on Nasdaq

15.40USD
24 Feb 2017
Change (% chg)

$0.30 (+1.99%)
Prev Close
$15.10
Open
$15.05
Day's High
$15.50
Day's Low
$14.88
Volume
1,034,637
Avg. Vol
673,875
52-wk High
$19.90
52-wk Low
$7.86

Select another date:

Tue, Feb 21 2017

BRIEF-Momenta Pharmaceuticals Q4 earnings per share $0.60

* Momenta Pharmaceuticals reports fourth quarter and year end 2016 financial results

BRIEF-Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa

* Momenta Pharmaceuticals announces FDA warning letter to contracted glatopa (glatiramer acetate injection) fill/finish manufacturer

BRIEF-Momenta Pharmaceuticals announces HSR clearance

* Momenta Pharmaceuticals announces Hart-Scott-Rodino clearance for collaboration and license agreement with CSL

BRIEF-Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation

* Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation Source text for Eikon: Further company coverage:

BRIEF-Momenta provides year-end 2016 corporate update

* Momenta Pharmaceuticals Inc - reiterated its non-gaap operating expense guidance of approximately $40 - $45 million for Q4 of 2016

Momenta's Humira biosimilar succeeds in key psoriasis study

U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

UPDATE 1-Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

BRIEF-Momenta Pharmaceuticals says positive top-line phase 3 results for M923, a proposed Humira biosimilar

* Momenta Pharmaceuticals announces positive top-line phase 3 results for M923, a proposed Humira (adalimumab) biosimilar

Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech company Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

BRIEF-Momenta Pharmaceuticals names Scott Storer as CFO

* Says Storer is expected to begin at Momenta on november 28, 2016 and will replace Momenta's current CFO Rick Shea

Select another date:

More From Around the Web